Yi-Long Wu

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

S. Thongprasert, P. Sunpaweravong, B. Margono, 2009, The New England journal of medicine.

Haem oxygenase-1 plays a central role in NNK-mediated lung carcinogenesis

M. Underwood, Ming Li, T. Mok, 2008, European Respiratory Journal.

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.

G. Giaccone, T. Ciuleanu, W. Brugger, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS).

E. Duffield, Y. Rukazenkov, Li Zhang, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.